These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22720768)

  • 1. Adverse events following vaccination in the French armed forces: An overview of surveillance conducted from 2002 to 2010.
    Mayet A; Haus-Cheymol R; Bouaiti EA; Decam C; Simon F; Mérens A; Spiegel A; Meynard JB; Deparis X; Migliani R
    Euro Surveill; 2012 Jun; 17(24):. PubMed ID: 22720768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012.
    Mayet A; Duron S; Meynard JB; Koeck JL; Deparis X; Migliani R
    Public Health; 2015 Jun; 129(6):763-8. PubMed ID: 25890634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in reported adverse events following seasonal influenza vaccination among the French armed forces, 2008-2009: possible role of stimulated reporting and background cases of influenza-like infection.
    Mayet A; Nivoix P; Haus-Cheymol R; De Laval F; Verret C; Duron S; Faure N; Piarroux M; Decam C; Chaudet H; Meynard JB; Deparis X; Migliani R
    Public Health; 2012 Jan; 126(1):70-6. PubMed ID: 22137096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces--2009-2010.
    Mayet A; Ligier C; Gache K; Manet G; Nivoix P; Dia A; Haus-Cheymol R; Verret C; Duron S; Faure N; Piarroux M; De Laval F; Simon F; Decam C; Chaudet H; Meynard JB; Rapp C; Deparis X; Migliani R
    Vaccine; 2011 Mar; 29(14):2576-81. PubMed ID: 21296693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual report: Surveillance of adverse events following immunisation in Australia, 2005.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A(H1N1) influenza surveillance in the French armed forces: adapting the surveillance systems to the pandemic setting].
    Mayet A; Pommier de Santi V; Manet G; Nivoix P; Ligier C; Faure N; Haus-Cheymol R; Piarroux M; Dia A; Duron S; Tanti M; De Laval F; Camara K; Queyriaux B; Nicand E; Decam C; Chaudet H; Meynard JB; Deparis X; Migliani R
    Med Mal Infect; 2010 Jul; 40(7):404-11. PubMed ID: 20381985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
    Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting?
    McNeil MM; Arana J; Stewart B; Hartshorn M; Hrncir D; Wang H; Lamias M; Locke M; Stamper J; Tokars JI; Engler RJ
    Vaccine; 2012 Mar; 30(14):2421-6. PubMed ID: 22310205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurologic adverse events associated with smallpox vaccination in the United States--response and comment on reporting of headaches as adverse events after smallpox vaccination among military and civilian personnel.
    Schumm WR
    BMC Med; 2006 Nov; 4():27. PubMed ID: 17096855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSW annual report describing adverse events following immunisation, 2010.
    Mahajan D; Campbell-Lloyd S; Cook J; Menzies RI
    N S W Public Health Bull; 2011 Nov; 22(9-10):196-208. PubMed ID: 22060057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.